2-(吡啶-2-基甲基)胍,硫酸 | 108833-93-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 中文名称: 2-(吡啶-2-基甲基)胍,硫酸
• 英文名称: 1-(2-pyridylmethyl) guanidine sulfate
• 英文别名: 1-(pyridin-2-ylmethyl)-guanidine sulfate；2-(pyridin-2-ylmethyl)guanidine;sulfuric acid
• CAS: 108833-93-8
• 化学式: C₇H₁₀N₄*H₂O₄S
• 分子量: 248.263
• InChiKey: XDNWWNJGHXLXRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.59
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(吡啶-2-基甲基)胍,硫酸 生成 1-acetyl-3-(pyridin-2-ylmethyl)-guanidine
  参考文献：
  名称：

  STUDT, W. L.;ZIMMERMAN, H. K.

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨甲基吡啶 、 S-甲基异硫脲硫酸盐 以 乙醇 、 水 为溶剂， 反应 18.0h， 以21%的产率得到2-(吡啶-2-基甲基)胍,硫酸
  参考文献：
  名称：

  Benzylguanidines and Other Galegine Analogues Inducing Weight Loss in Mice

  摘要：

  Dimethylallylguanidine, also known as galegine, isolated from Galega officinalis, has been shown to have weight reducing properties in vivo. Substitution of the guanidine group with an N-cyano group and replacement of guanidine with amidine, pyrimidine, pyridine, or the imidazole moieties removed the weight reducing properties when evaluated in BALB/c mice. However, retention of the guanidine and replacement of the dimethylallyl group by a series of functionalized benzyl substituents was shown to exhibit, and in some cases significantly improve, the weight reducing properties of these molecules in BALB/c, ob/ob, and diet induced obesity (DIO) mice models. The lead compound identified, across all models, was 1-(4-chlorobenzyl)guanidine hemisulfate, which gave an average daily weight difference (% from time-matched controls; +/- SEM) of -19.7 +/- 1.0, -11.0 +/- 0.7, and -7.3 +/- 0.8 in BALB/c, ob/ob, and DIO models, respectively.

  DOI：

  10.1021/jm8011933

文献信息

• Heterocyclic amidino substituted ureas and their pharmaceutical uses
  申请人：Rorer Pharmaceutical Corporation

  公开号：US04707478A1

  公开（公告）日：1987-11-17

  This invention relates to methods for the prophylactic and curative treatment of gastrointestinal and cardiovascular disorders and parasitic infections in humans and animals, using a class of hetrocyclic amidino substituted urea and thiourea compounds, a novel class of heterocyclic amidino substituted urea and thiourea compounds and pharmaceutical compositions and animal feed additives including the same.

  本发明涉及使用一类杂环氨基甲酰基取代的脲和硫脲化合物，一种新的杂环氨基甲酰基取代的脲和硫脲化合物以及包括它们的制药组合物和动物饲料添加剂，用于预防和治疗人和动物的胃肠道和心血管疾病以及寄生虫感染。
• 1-Pyridylmethyl-3-acyl guanidines
  申请人：William H. Rorer, Inc.

  公开号：US04496573A1

  公开（公告）日：1985-01-29

  1-Acyl-3-pyridyl guanidine and 1-acyl-3-pyridylalkyl guanidine compounds, methods for the treatment of blood pressure disorders, including hypertension, in humans and other mammals.

  1-Acyl-3-pyridyl guanidine和1-acyl-3-pyridylalkyl guanidine化合物，以及用于治疗人类和其他哺乳动物的血压紊乱，包括高血压的方法。
• [EN] 1-ACYL-3-PYRIDYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS
  申请人：——

  公开号：WO1984000963A1

  公开（公告）日：1984-03-15

  (EN) 1-Acyl-3-pyridyl guanidine and 1-acyl-3-pyridylalkyl guanidine compounds, methods for the treatment of blood pressure disorders, including hypertension, in humans and other mammals. (FR) Composés de 1-acyl-3-pyridylguanidine et de 1-acyl-3-pyridylalkylguanidine, procédés pour le traitement de troubles de la pression artérielle, dont l'hypertension, chez les être humains et les autres mammifères.

  1-酰基-3-吡ridyl-尿素和酰基-3-吡ridyl-酰胺化合物，用于治疗人类和其他哺乳动物动脉压力问题（包括高血压）的方法。
• Long-acting dihydropyridine calcium antagonists. 3. Synthesis and structure-activity relationships for a series of 2-[(heterocyclylmethoxy)methyl] derivatives
  作者：David Alker、Simon F. Campbell、Peter E. Cross、Roger A. Burges、Anthony J. Carter、Donald G. Gardiner

  DOI：10.1021/jm00130a026

  日期：1989.10

  The preparation of 1,4-dihydropyridines containing (heterocyclylmethoxy)methyl groups in the 2-position is described and the structural identification of certain of the compounds using 1H NMR spectroscopic methods is reported. The calcium antagonist activity of the compounds on rat aorta is listed and is compared with the negative inotropic potency as determined by using a Langendorff-perfused guinea pig heart model. Several compounds are more potent than nifedipine and show greater selectivity for the vasculature over the heart. One compound, 2-[(2-amino-4-hydroxypyrimidin-6-yl)methoxy]-4- (2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl- 1,4-dihydropyridine (27, UK-56,593), was identified as a potent (IC50 = 1.6 x 10(-9) M), tissue-selective calcium antagonist which proved to have a markedly longer duration of action (greater than 4.5 h) than nifedipine in the anesthetized dog on intravenous administration.
• ALKER, DAVID;CAMPBELL, SIMON F.;CROSS, PETER E.;BURGES, ROGER A.;CARTER, +, J. MED. CHEM., 32,(1989) N0, C. 2381-2388
  作者：ALKER, DAVID、CAMPBELL, SIMON F.、CROSS, PETER E.、BURGES, ROGER A.、CARTER, +

  DOI：——

  日期：——